Coeptis Therapeutics (NASDAQ:ZSQR) Shares Down 12.1% – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price fell 12.1% during trading on Monday . The stock traded as low as $14.53 and last traded at $14.70. 115,379 shares traded hands during trading, a decline of 10% from the average session volume of 128,262 shares. The stock had previously closed at $16.73.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Coeptis Therapeutics Trading Down 12.9%

The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $749.34 million, a P/E ratio of -5.78 and a beta of -0.22. The firm’s 50-day simple moving average is $12.28 and its 200 day simple moving average is $12.83.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Yorkville Advisors Global LP purchased a new position in shares of Coeptis Therapeutics in the third quarter worth approximately $140,000. Geode Capital Management LLC lifted its position in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after acquiring an additional 4,721 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares during the period. State Street Corp grew its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Coeptis Therapeutics during the 4th quarter worth approximately $259,000. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.